Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22098400 | 1.00 | CYP2C19 (0.74) | CYP2C19ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL23309348 | 1.00 | CYP2C19 (0.74) | CYP2C19ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL23309218 | 0.91 | CYP2C19 (0.73) | CYP2C19ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL12215903 | 0.88 | CYP2C19 (0.79) | CYP2C19ALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL29641976 | 0.88 | CYP2C19 (0.69) | CYP2C19ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL612760 | 0.86 | CYP2C19 (1.00) | CYP2C19ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL1000556 | 0.85 | CYP2C19 (0.78) | CYP2C19ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL22070846 | 0.85 | CYP2C19 (0.78) | CYP2C19ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL7694604 | 0.85 | ALDH1A1 (0.77) | CYP2C19ALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL22070944 | 0.85 | AKR1C3 (0.64) | CYP2C19ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP2C19 1/4885ALDH1A1 378/4885RAB9A 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.